Commentary on “Dynamic evolution of the global burden of chronic urticaria: a comprehensive trend analysis from 1990 to 2021 and projections to 2050”

Dear Editor, We read with great interest the study by Cao and colleagues, who used Global Burden of Disease (GBD) 2021 estimates to characterize long-term trends in urticaria incidence, prevalence, and disability-adjusted life-years (DALYs) from 1990 to 2021, and to project the future burden through 2050[1]. Their findings carry a clear public health implication: even when age-standardized rates remain broadly stable, absolute case counts and DALYs can rise substantially as populations grow and age, with notable regional variation and consistently higher burden among females and children younger than 5 years[1]. First, the apparent gap between relatively stable age-standardized rates and the marked growth in absolute counts would be more informative for policy if the drivers were quantified explicitly. A formal decomposition separating population growth, population ageing, and epidemiological rate change – presented overall and stratified by SDI – could help readers distinguish settings where service demand is primarily demographic from those where prevention or environmental mitigation may offer the greatest gains[2,3]. Second, interpretation of cross-regional differences may be strengthened by making uncertainty and ranking stability more transparent. Because GBD estimates are reported with uncertainty intervals, it would be helpful to indicate whether regional orderings remain consistent when uncertainty is considered (for example, by reporting overlap-aware comparisons or a brief rank-uncertainty summary). This may reduce over-interpretation of small between-region contrasts and support more confident priority setting[1,3]. Finally, the projections to 2050 are a major contribution, yet readers would benefit from fuller reporting of forecast uncertainty and model performance. Alongside point estimates from ARIMA and exponential smoothing, presenting prediction intervals and a simple out-of-sample evaluation (e.g., training through an earlier year and testing on more recent observations) could demonstrate calibration and help avoid undue precision in long-horizon projections[4]. In conclusion, this work offers a valuable global synthesis of urticaria burden and its future trajectory. Decomposing the drivers of absolute burden growth, incorporating uncertainty-aware regional comparisons, and reporting forecast uncertainty more fully may further enhance interpretability and translation into pragmatic public health planning[1].